AI Article Synopsis

  • There is currently no agreement among major medical organizations on the fixed dosage of radioactive iodine (RAI) for treating Graves' disease, prompting this study to evaluate a standard dose of 15 mCi ±10%.
  • A retrospective review of patient charts from 2014 to 2020 identified 67 cases of hyperthyroidism due to Graves' disease, categorizing the outcomes based on the 15 mCi ±10% dosage effectiveness.
  • Results showed that a high percentage (89.55%) of patients became hypothyroid after treatment, suggesting that a standardized low dose could simplify treatment protocols and eliminate the need for complex calculations in determining thyroid weight for RAI treatments.

Article Abstract

Introduction: Currently, there is a lack of consensus on the fixed dosage of RAI to be administered for this purpose between the main guideline frameworks set forth by the American Thyroid Association (ATA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM) and the European Thyroid Association (ETA). In this retrospective study, we will investigate the effectiveness of using a standard dose of 15 mCi ±10% of RAI in the treatment of Graves'.

Methods: A retrospective chart review was conducted for the period between 1 May 2014 and 2 September 2020, to identify patients diagnosed with hyperthyroidism due to Graves' disease. The patients were grouped based on outcome and assessed for the efficacy of the dosage of 15 mCi ±10% of RAI in a successful treatment.

Results: Sixty-seven patients were identified that met the inclusion criteria between 1 May 2014 and 2 September 2020. Of the 67 RAI ablations; 60 patients became hypothyroid [60/67, (89.55%)], 2 euthyroid [2/67, (2.99%)] and 5 remained hyperthyroid [5/67, (7.46%)].

Conclusions: For the treatment of Graves' disease, the use of a standard low dose of 15 mCi ±10% has a high success rate without additional measurements or calculations beyond a standard planar image and 24-h uptake %. The adoption of a standard low dose of 15 mCi of I-131 across institutional guidelines would streamline dosage questions and eliminate the need to determine the weight of the thyroid for calculations in all RAI treatments for hyperthyroidism caused by Graves' disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000001633DOI Listing

Publication Analysis

Top Keywords

graves' disease
16
dose 15 mci
12
15 mci ±10%
12
treatment graves'
8
thyroid association
8
nuclear medicine
8
±10% rai
8
2014 september
8
september 2020
8
standard low
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!